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Background: Hemoglobin A1c is the main treatment target for patients with type 2 diabetes. It has also been
shown recently that postprandial glucose and daily glucose fluctuations affect the progression of diabetic
complications and atherosclerotic damages.
Methods: Continuous glucose monitoring was performed in patients with type 2 diabetes to evaluate the efficacy
of repaglinide vs. glimepiride on postprandial glucose spikes and fluctuations. A total of 10 Japanese patients with
type 2 diabetes treated with glimepiride monotherapy were enrolled. After observation period for 8 weeks,
glimepiride was changed to repaglinide. Continuous glucose monitoring was performed whilst consuming calorie-
restricted diets for two days at baseline and at the end of the 12-week trial. Blood and urine samples were collected
for measurement of glucose control parameters and inflammatory and oxidative stress markers on the last day of
taking either glimepiride or repaglinide.
Results: Nine patients completed the trial. Although the glucose control parameters were not significantly different
between glimepiride and repaglinide, the mean amplitude of glycemic excursions measured by continuous glucose
monitoring was significantly reduced by changing treatment from glimepiride to repaglinide. The levels of
plasminogen activator inhibitor-1, high sensitivity C-reactive protein, and urinary 8-hydoroxydeoxyguanosine were
reduced significantly by repaglinide treatment.
Conclusion: These results suggest that repaglinide may decrease the risk of cardiovascular disease in type 2
diabetes by minimizing glucose fluctuations thereby reducing inflammation and oxidative stress.
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Inflammation and oxidative stress have emerged as im-
portant factors in atherosclerosis, and have therefore
attracted clinical attention as novel risk factors for cardio-
vascular diseases (CVD). Some studies in patients with
diabetes have shown that serum inflammation markers,
such as high-sensitivity C reactive protein (hs-CRP),
interleukin-6 (IL-6), interleukin-10 (IL-10) and tumor ne-
crosis factor-α (TNF-α), and oxidative stress markers,
such as urinary 8-hydoroxydeoxyguanosine (u-8-OHdG)* Correspondence: masahiro@koto.kpu-m.ac.jp
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unless otherwise stated.and 8-iso-prostaglandin F (2α) (u-8-isoPGF2α), were asso-
ciated clearly with future coronary events [1-5].
Hemoglobin A1c (HbA1c) is the main target for pa-
tients with type 2 diabetes. However, postprandial glu-
cose levels have been shown to be closely associated
with increased CVD [6]. It has been reported that activa-
tion of either inflammation or oxidative stress by post-
prandial hyperglycemia is an important mechanism in
the pathogenesis of atherosclerosis [7]. Glucose fluctua-
tions during postprandial periods have a more specific
triggering effect on oxidative stress than chronic sus-
tained hyperglycemia [8]. Therefore, acute glucose
swings should be targeted as an anti-atherosclerotic
strategy in the treatment of type 2 diabetes.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Yamazaki et al. Diabetology & Metabolic Syndrome 2014, 6:54 Page 2 of 7
http://www.dmsjournal.com/content/6/1/54Sulfonylurea agents (SUs) such as glimepiride are used
widely to treat patients with type 2 diabetes, although
they do not reduce glucose swings. On the other hand,
repaglinide, a meal-time insulin secretagogue approved
for treatment of type 2 diabetes, reduces postprandial
blood glucose (PBG) peaks, lowers 24-h blood glucose
(BG) profiles, and reduces HbA1c levels [9-11]. Animal
experiments have demonstrated that repaglinide also has
an anti-oxidative effect [12]. There is also evidence that
progression of carotid intima-media thickness in patients
treated with repaglinide is significantly attenuated com-
pared with treatment with SUs [13,14]. These findings
suggest that repaglinide has anti-inflammatory and anti-
oxidative effects by reducing glucose fluctuations. The
mean amplitude of glycemic excursions (MAGE) calcu-
lated from continuous glucose monitoring (CGM) is the
gold standard for evaluating glucose variability. However,
no studies have demonstrated differences between the
effects of repaglinide and SUs on glucose fluctuations
based on data obtained from CGM devices.
In this study, we assessed the effects of repaglinide
treatment on PBG peaks and glucose fluctuations using
CGM, and compared changes in oxidative stress and in-
flammation markers with those measured during glime-
piride treatment.
Subjects and methods
Study subjects and protocol
The subjects were recruited from the outpatient clinic at
Hospital of Kyoto Prefectural University of Medicine be-
tween July 2012 and October 2013. The subjects were
patients with type 2 diabetes older than 20 years. All the
patients were treated with a stable dosage of glimepride
only and had stable glycemic control (stable HbA1c
levels between 7.0 ~ 8.0% for at least 8 weeks before in-
clusion). Patients with severe chronic diabetic complica-
tions, heart failure, liver dysfunction, renal dysfunction,
inflammatory diseases, or malignancies were excluded.
All recruited patients with major cardiovascular eventFigure 1 Study protocol. The patients were treated with glimepiride mon
treatment to repaglinide, the patients were monitored for 12 weeks to ens
collected, and CGM was performed at the end of both treatment periods.history were excluded from this study. The purpose and
risks of the study were explained to all the subjects, and
informed consent was obtained prior to enrollment. The
study was approved by the Ethical Committee of the
Kyoto Prefectural University of Medicine.
The study protocol is summarized in Figure 1. After
recruitment, all the patients were treated with glimepir-
ide monotherapy for 8 weeks under normal daily life
conditions, followed by the first CGM. The dosage of
glimepiride was not changed until the first CGM was
completed. The first CGM was performed for 3 days
(72 hours). On the second and third days of monitoring,
the patients had calorie-adjusted meals delivered to their
homes (mealtime; FUNDERY Co., Ltd., Tokyo, Japan)
that consisted of a breakfast, lunch and dinner (440 ~
510 kcal, protein 18 g, fat 9 g, carbohydrate 52 ~ 67 g in
each meal). On the last day of CGM, fasting blood sam-
ples were collected for measurement of fasting blood
glucose (FBG), HbA1c, glycoalbumin (GA), 1,5-anhydro-
glucitol (1,5-AG), and insulin. The same samples were
used to measure inflammatory markers including plas-
minogen activator inhibitor-1 (PAI-1), IL-6, and hs-CRP.
U-8-OHdG and u-8-isoPGF2α were measured in spot
urine samples collected at the same time. The day after
the first CGM, glimepiride was changed to repaglinide
as follows: 0.5 mg, 1.0 mg and 2.0 mg of glimepiride
once a day in the morning were changed to 0.125 mg,
0.25 mg, and 0.5 mg of repaglinide 3 times a day just be-
fore meals, respectively. After 4 weeks of repaglinide
treatment the patients had blood tests to confirm they
had no side effects and stable glycemic control. After
12 weeks of repaglinide treatment, a second CGM was
performed using the same protocol as the first CGM.
Blood and urine tests were also performed as described
above.
Analytical methods
Plasma glucose was determined by a standard laboratory
assay. Plasma insulin, C-peptide, and IL-6 were analyzedotherapy for 8 weeks to achieve glycemic control. After changing
ure they had stable glucose control. Blood and urine samples were
Table 1 Comparison the clinical and laboratory markers
at glimepiride treatment and repaglinide treatment
Glimepiride Repaglinide p
Number (male) 9 (7) 9 (7) -
Age (years) 68.0 ± 6.5 - -
Duration (years) 18.3 ± 12.8 - -
Body weight (kg) 64.3 ± 12.7 64.2 ± 12.3 0.86
Body mass index (kg/m2) 24.7 ± 3.7 24.7 ± 3.7 0.91
Dose (mg) 1.0 ± 0.4 0.75 ± 0.32 -
sBP (mmHg) 132.6 ± 4.2 126.2 ± 3.8 0.42
dBP (mmHg) 74.6 ± 4.0 70.6 ± 3.8 0.47
HbA1c (%) 7.0 ± 0.2 7.0 ± 0.2 0.62
FBS (mmol/L) 7.8 ± 1.9 7.7 ± 1.5 0.78
GA (%) 17.2 ± 1.7 17.3 ± 1.3 0.84
1,5-AG(mg/ml) 7.1 ± 3.3 7.1 ± 3.6 0.96
IRI (mU/ml) 6.0 ± 2.6 5.2 ± 3.6 0.41
s-CPR(mg/dl) 2.3 ± 1.9 1.6 ± 0.7 0.17
HOMA-IR 2.4 ± 1.7 2.1 ± 1.1 0.17
HOMA-β 33.7 ± 16.3 30.9 ± 15.8 0.15
Data are expressed as means ± SD. sBP, systolic blood pressure; dBP, diastolic
blood pressure; HbA1c, hemoglobin A1c; FBS, fasting blood glucose; GA,
glycoalbumin; 1,5-AG, anhydroglucitol; IRI, immunoreactive insulin; s-CPR,
serum C-peptide immunoreactivity.
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performance liquid chromatography and expressed as
National Glycohemoglobin Standardization Program
Units. GA, 1,5-AG, u-8-OHdG, and u-8-iso PGF2α were
analyzed by EIA, and PAI-1 by the LPIA-tPAI test (SRL,
Tokyo, Japan).
CGM was performed using a i-Pro2 digital recorder
(MiniMed, Medtronic, Northridge, CA, USA). MAGE,
the standard deviation (SD) of blood glucose level, mean
blood glucose level (mean BG), percent of hours under
3.9 mmol/L of serum glucose in 24 hours and percent of
hours over 10.0 mmol/L of serum glucose in 24 hours
were calculated from the glucose curve on day 3 in
order to exclude the influence of the meals on the first
day of CGM.
Statistical methods
Data in the tables and figures were expressed as mean ±
SD, with the exception of CGM (mean ± SEM). The ef-
fects of changing treatment were analyzed using paired t
test. All the statistical analyses were performed using
PRISM5 software (GraphPad Software, Inc., CA, USA).
Results
Clinical characteristics at baseline
Ten patients were enrolled in the study, with a total of 9
patients completing the trial. One patient was withdrawn
because of gastrointestinal symptoms caused by repagli-
nide. All the patients were Japanese with a mean age of
68.0 ± 6.5 years and HbA1c of 7.0 ± 0.2% (range 6.7 ~
7.2%). The estimated duration of diabetes was 18.3 ±
12.8 years (range 5 ~ 44 years). The mean dose of glime-
piride was 1.0 ± 0.4 mg/day. Six of the participants were
treated with anti-hypertensive agents; two with angioten-
sin II receptor blocker (ARB) only;two with Ca blocker
only, and; two with ARB and Ca blocker. One participant
was treated with acetyl salicylic acid. Any changes of anti-
hypertensive, anti-platelet, and anti-lipid agents during the
current study were not done. The other baseline data are
shown in Table 1 (glimepiride treatment group).
The effects on body weight, BMI, and glycemic control
After 12 weeks of treatment with repaglinide, there were no
significant changes in body weight or BMI (Table 1). None
of the glucose control parameters (HbA1c, GA, and 1,5-
AG) were changed by repaglinide treatment. Homeostasis
model assessment indices of insulin resistance (HOMA-IR)
and β-cell function (HOMA-β) were comparable with gli-
mepiride or repaglinide treatment (Table 1).
The effects on parameters of daily glucose change
The 24-h blood glucose profiles in day 3 of CGM are
shown in Figure 2. One of the nine patients declined to
undergo CGM. In the remaining eight patients, the SDfor blood glucose levels and mean BG were similar be-
tween the two treatments (Table 2). In contrast, MAGE, a
marker of daily glucose fluctuations, decreased signifi-
cantly with repaglinide treatment (Table 2. glimepiride,
108.0 ± 55.5 vs. repaglinide, 65.1 ± 30.4; P < 0.05). The
mean percent of hours over 10.0 mmol/L of serum glu-
cose in 24 hours at repaglinide treatment was significantly
lower than that at glimepiride treatment (Table 2. glime-
piride, 31.3 ± 27.1% vs. repaglinide, 10.1 ± 10.5%; p < 0.05).
The effects on markers of blood inflammation and urine
oxidative stress
The levels of plasma PAI-1 (Figure 3. glimepiride, 28.9 ±
13.5 vs. repaglinide, 22.5 ± 11.6; P < 0.05) and hs-CRP
(Figure 3. glimepiride, 580.3 ± 339.7 vs. repaglinide,
382.3 ± 191.1; P < 0.05) were decreased significantly fol-
lowing repaglinide treatment compared with glimepiride
treatment. On the other hand, there was no significant
change in plasma IL-6 levels.
U-8-OHdG and u-8-isoPGF2α were measured to assess
the effect on oxidative stress. The level of u-8OHdG
was decreased significantly with repaglinide treatment
(Figure 4. glimepiride, 10.9 ± 2.7 vs. repaglinide, 9.2 ± 3.5;
P < 0.05), whereas u-8-isoPGF2α, was not.
Discussion
This study on patients with type 2 diabetes on glimepir-
ide showed that a change in treatment to repaglinide
Figure 2 Blood glucose profiles measured by CGM during glimepiride or repaglinide treatment (n = 8). Glimepiride was taken once a day
in the morning, while repaglinide was taken three times a day before every meal. The blood glucose profiles on day 3 are shown for all patients.
The effects of the meal with unrestricted calories consumed on day 1 and 2 were excluded from the analyses. Blight shade area shows mean ±
SEM of serum glucose levels during glimepiride treatment. Dark shade area shows mean ± SEM of serum glucose levels during repaglinide
treatment.
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(PAI-1, hs-CRP) and oxidative stress markers (u-8-OHdG),
despite glucose control parameters (HbA1c, GA, and mean
BG) remaining unchanged. We also demonstrated that
repaglinide improved postprandial glucose excursions and
MAGE assessed by CGM following calorie-adjusted meals.
Repaglinide is an insulin secretagogue agent with a
more rapid anti-hyperglycemic action and a shorter dur-
ation than SUs, and therefore provides better control of
postprandial hyperglycemia [15,16]. In this study, the
smaller fluctuations in blood glucose levels with repagli-
nide treatment were consistent with the pharmacody-
namic properties of this agent.
The mean level of glycemia assessed by HbA1c is a
well known risk factor for the development of diabeticTable 2 Parameters calculated by CGM during
glimepiride or repaglinide treatment
glimepiride repaglinide p
Max-BG(mmol/L) 13.5 ± 2.9 12.7 ± 3.6 0.51
Min-BG(mmol/L) 5.6 ± 0.9 5.3 ± 1.3 0.58
Max-Min (mmol/L) 7.9 ± 2.8 7.4 ± 3.4 0.63
SD (mmol/L) 1.9 ± 0.8 1.8 ± 1.0 0.78
Mean BG(mmol/L) 8.7 ± 1.6 8.0 ± 1.5 0.33
MAGE(mmol/L) 6.0 ± 3.1 3.6 ± 1.7 <0.05
Hours of under 3.9 mmol/L
(% 24 hours)
0 0 -
Hours of over 10.0 mmol/L
(% 24 hours)
31.3 ± 27.1 10.1 ± 10.5 <0.05
Data are expressed as means ± SD. BG, blood glucose; Max-Min, difference
between Max-BG and Min-BG; SD, standard deviation; MAGE, mean amplitude
of glycemic excursions.vascular complications. However, recent studies have
suggested that blood glucose variability is more deleteri-
ous than a constant high glucose as it accelerates dia-
betic macrovascular complications [17]. Xiao-min et al.
reported that parameters of glycemic variability calcu-
lated from CGM data, such as SD and MAGE, were in-
creased as atherosclerosis progressed in patients with
type 2 diabetes, and that increases in carotid intima-
media thickness correlated significantly with MAGE
[18]. Furthermore, accumulated data have indicated
there is a significant relationship between glucose fluctu-
ations and oxidative stress that may lead to the develop-
ment of atherosclerosis. A recent study demonstrated that
chronic blood glucose variability induced chronic inflam-
mation as assessed by blood hs-CRP levels, a marker that is
recognized as a significant predictor of cardiovascular
events [19]. Based on these reports, we assume that the
smaller fluctuations in glucose levels we observed following
repaglinide treatment compared with glimepiride treatment
may have decreased the level of inflammation and oxidative
stress biomarkers. These data raise the possibility that long-
term repaglinide treatment may be beneficial for preventing
macrovascular complications in type 2 diabetes.
Rizzo et al. also demonstrated using data from a meal-
test that repaglinide was more efficient than glimepiride
for controlling postprandial glucose excursions and re-
ducing oxidative stress and inflammation markers. The
duration of chronic sustained hyperglycemia and the
acute fluctuations in glucose levels are two factors that
contribute to diabetic complications. The measurement
of MAGE is strongly recommended for predicting inci-
dent cardiovascular events [20,21]. CGM is the only
Figure 3 Inflammation markers measured by in blood samples collected during treatment with either glimepiride or repaglinide.
(A) PAI-1, (B) IL-6, and (C) hs-CRP levels are shown (n = 9). *p < 0.001; **p < 0.05.
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fluctuation parameters including MAGE. It has also
been reported that oxidative stress markers (u-8-iso-
PGF2α, serum 8-OHdG) and chronic inflammation
marker (hs-CRP) correlate positively with MAGE, but
not with HbA1c or FBS [22]. The present study confirmed
the benefit of repaglinide treatment by incorporating de-
tailed analysis of acute glucose fluctuations using CGM
and simultaneous measurements of inflammation and oxi-
dative stress markers under normal daily living conditions.
Furthermore, the percent of hours over 10.0 mmol/L of
serum glucose calculated by CGM at repaglinide treat-
ment was lower than that at glimepiride treatment. This
shorter exposure of hyperglycemia might contribute to de-
crease of inflammatory and oxidative stress markers.Figure 4 Oxidative stress markers measured in urine samples collecte
(A) u-8-OHdG and (B) u-8-isoPGF2α levels are shown (n = 9). *p < 0.05.The NAVIGATOR study, a large international placebo-
controlled trial, did not demonstrate the validity of nate-
glinide (a short-acting insulin secretagogue) for reduction
of the incidence of diabetes and cardiovascular events in
the patients of impaired glucose tolerance [23]. It may be
argued that this finding is contradictable with our current
results predicting the suppressive effect of repaglinide, an-
other short-acting insulin secretagogues, on inflammation
and oxidative stress in type 2 diabetes patients. However,
it should be noted that, in the NAVIGATOR study, the
nateglinide treatment group was associated with greater
body weight gain and failure of suppression of postpran-
dial hyperglycemia. Therefore, we cannot refer to the sig-
nificance of suppression of post-prandial hyperglycemia
from the results of NAVIGATOR study. In addition, it hasd during treatment with either glimepiride or repaglinide.
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lowering effect than nateglinide [24].
Many of the limitations stem from our sample size,
which limits our statistical power to observe associa-
tions, although we conducted this study with the well
controlled protocol and the selected subjects with the
well-designed inclusion/exclusion criteria. We assumed
that the other factors than the anti-diabetics, such as ha-
bitual and environmental factors, didn’t change during
three months of the intervention period. In general,
three months of the intervention period is considered to
be appropriate for estimation of the merely drug effect.
Actually, we confirmed that the patients’ physical condi-
tions and lifestyles didn’t change every 4 week. Further-
more, setting the control group would help elucidating
the mechanism underlying the drug effect.
Conclusion
Repaglinide treatment is more beneficial than glimepiride
for decreasing glucose variability in patients with type 2
diabetes. These smaller glucose fluctuations are associated
with decreased levels of inflammation and oxidative stress
markers. This change is important as it has the potential
benefit of reducing CVD risk in patients with type 2
diabetes.
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